Creative Biolabs offers comprehensive PARP Assay Services tailored to investigate enzyme kinetics, inhibitor profiling, and immune-related functions of PARP enzymes, supporting immuno-oncology research and drug discovery.
Poly(ADP-ribose) polymerases (PARPs) are key regulators of DNA damage response (DDR) and post-translational modification through poly-ADP-ribosylation (PARylation). Among the 17 PARP family members, PARP1 and PARP2 play prominent roles in sensing DNA strand breaks and orchestrating repair. Beyond genome maintenance, PARPs have emerged as critical immunomodulators by influencing STING signaling, immunogenic cell death (ICD), and tumor antigenicity. Inhibiting PARPs can enhance the efficacy of immunotherapy through cGAS-STING pathway activation and PD-L1 expression modulation.
We provide diverse biochemical and cellular tools for evaluating PARP functions in the context of tumor–immune interactions:
Quantitative analysis of NAD⁺ conversion to poly(ADP-ribose) using antibody-based detection of PAR chains
Real-time monitoring of PARP1/2 activity using labeled NAD⁺ analogs or biotinylated PAR substrates
High-sensitivity detection of [³²P]-NAD⁺ incorporation onto nuclear acceptor proteins
Quantification of PAR levels in tumor or immune cells post-DNA damage induction, including immunogenic stress conditions
Evaluation of cGAS-STING activation following PARP inhibition or hyperactivation in tumor-immune co-culture models
Screening libraries against PARP1, PARP2, or tankyrase isoforms in 96/384-well formats with IC₅₀ reporting
A1: Yes, we utilize isoform-selective substrates and inhibitors to distinguish PARP1 from PARP2 or tankyrase activity.
A2: Absolutely. We integrate cGAS-STING activation, cytokine release assays, and PD-L1 expression analysis post-PARP modulation.
A3: Our radiolabeled and fluorescence-based systems can detect PARP activity in the nanomolar range with high reproducibility.
A4: Yes. We routinely incorporate etoposide, doxorubicin, or ionizing radiation to model damage-induced PARylation and immune priming.
A5: We offer screening services using tumor and immune cell lines, including checkpoint-relevant backgrounds (e.g., PD-L1+, STING+ models).
Creative Biolabs empowers your research into DNA damage-induced immune responses through precise PARP activity measurements and mechanistic insights. Partner with us for tailored assay development and data-driven discovery.